PharmAbcine Inc.
June 18, 2025
Company Presentation
Ophthalmology
PharmAbcine is a clinical-stage public company, founded in 2008 during the global economic crisis with investment from Novartis and OrbiMed. We possess a fully human antibody library, a patient-derived cancer stem cell library, and a range of mono-specific and multi-specific antibodies.
PharmAbcine has two subsidiaries:
Wincal BioPharm, based in South San Francisco, has developed a novel eye drop formulation through its OPC platform. Wincal is currently preparing an IND for an Eylea eye drop product.
PharmAbcine Australia Pty Ltd, located in Brisbane, is a clinical-stage private company with two oncology pipelines: Olinvacimab, a next-generation VEGFR2-neutralizing human IgG (analogous to Cyramza), and PMC-309, a next-generation immune checkpoint inhibitor targeting VISTA. Both programs are supported by MSD (Merck & Co.) for combination trials with Keytruda.
Both Wincal BioPharm and PharmAbcine Australia Pty Ltd are actively seeking novel business development opportunities.
Company HQ City:
Daejeon,
Company HQ State:
Daejeon Metropolitan
Company HQ Country:
Korea, Republic of
Year Founded:
2008
Lead Product in Development:
Olinvacimab, PMC-309, PMC-403, PMC-005, PMC-201, PMC-122, PMC-TROP2
CEO
Peter Sim
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
7
Exchange
KOSDAQ
Ticker
208340
When you expect your next catalyst update?
phase i completion of PMC-403 within Q2 of 2025
What is your next catalyst (value inflection) update?
phase i completion of PMC-403 within Q2 of 2025
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}